SFPIA
CLDX icon

Stevens First Principles Investment Advisors’s Celldex Therapeutics CLDX Stock Holding History

Stevens First Principles Investment Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-40
Closed -$9K – 151
2015
Q4 		$9K Sell
40
-93
-70% -$20.3K 0.01% 157
2015
Q3 		$21K Buy
+133
New +$37.6K 0.02% 145
2014
Q1 		– Sell
-40
Closed -$15K – 205
2013
Q4 		$15K Sell
40
-7
-15% -$2.7K 0.01% 170
2013
Q3 		$25K Sell
47
-153
-77% -$52.5K 0.01% 156
2013
Q2 		$47K Buy
+200
New +$39.4K 0.03% 133

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Stevens First Principles Investment Advisors's CLDX Position: Q1 2016 in Review

Stevens First Principles Investment Advisors sold out of Celldex Therapeutics (CLDX) in Q1 2016, closing a stake of 40 shares — an estimated $9K sold.

Stevens First Principles Investment Advisors first reported a position in CLDX in Q2 2013 and held it in 5 quarters. The position peaked at $47K in Q2 2013. 145 funds tracked by Wall St. Rank hold CLDX as of Q1 2016.

  • Stevens First Principles Investment Advisors reported no remaining Celldex Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Stevens First Principles Investment Advisors sold 40 Celldex Therapeutics shares in Q1 2016, an estimated $9K.
  • Stevens First Principles Investment Advisors first reported a position in Celldex Therapeutics in Q2 2013 and held it in 5 quarters.
  • Stevens First Principles Investment Advisors's Celldex Therapeutics position peaked at $47K in Q2 2013.
  • 145 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2016.

Based on Stevens First Principles Investment Advisors's 13F filing for Q1 2016, filed 13 May 2016.